Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changchun Deng

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Genome Biology|December 4, 2004
Integrating phenotypic and expression profiles to map arsenic-response networksAstrid C Haugen, Ryan Kelley, Jennifer B Collins, et al.
Journal of Hematology & Oncology|December 1, 2016
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapyLorenzo Falchi, Ahmed Sawas, Changchun Deng, et al.
Molecular Systems Biology|June 2, 2006
Global analysis of gene function in yeast by quantitative phenotypic profilingJames A Brown, Gavin Sherlock, Chad L Myers, et al.
Molecular Cancer Research : MCR|December 29, 2005
Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiaeYijun Chen, Douglas E Feldman, Changchun Deng, et al.
British Journal of Haematology|December 17, 2016
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphomaMatko Kalac, Jennifer K Lue, Emily Lichtenstein, et al.
Experimental Hematology & Oncology|February 19, 2021
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphomaPatrick B Johnston, Amanda F Cashen, Petros G Nikolinakos, et al.
Leukemia & Lymphoma|July 29, 2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experienceAhmed Sawas, Helen Ma, John Kuruvilla, et al.
Molecular Cancer Therapeutics|June 10, 2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysLuigi Scotto, Cristina Kinahan, Eugene Douglass, et al.
British Journal of Haematology|February 22, 2017
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximabAhmed Sawas, Charles M Farber, Marshall T Schreeder, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Genome Biology|December 4, 2004
Integrating phenotypic and expression profiles to map arsenic-response networksAstrid C Haugen, Ryan Kelley, Jennifer B Collins, et al.
Journal of Hematology & Oncology|December 1, 2016
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapyLorenzo Falchi, Ahmed Sawas, Changchun Deng, et al.
Molecular Systems Biology|June 2, 2006
Global analysis of gene function in yeast by quantitative phenotypic profilingJames A Brown, Gavin Sherlock, Chad L Myers, et al.
Molecular Cancer Research : MCR|December 29, 2005
Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiaeYijun Chen, Douglas E Feldman, Changchun Deng, et al.
British Journal of Haematology|December 17, 2016
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphomaMatko Kalac, Jennifer K Lue, Emily Lichtenstein, et al.
Experimental Hematology & Oncology|February 19, 2021
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphomaPatrick B Johnston, Amanda F Cashen, Petros G Nikolinakos, et al.
Leukemia & Lymphoma|July 29, 2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experienceAhmed Sawas, Helen Ma, John Kuruvilla, et al.
Molecular Cancer Therapeutics|June 10, 2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysLuigi Scotto, Cristina Kinahan, Eugene Douglass, et al.
British Journal of Haematology|February 22, 2017
A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximabAhmed Sawas, Charles M Farber, Marshall T Schreeder, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
Pageof 4